Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05874037 · ClinicalTrials.gov registry record · Phase 2

Fluvoxamine for Long COVID-19

A Phase 2 study of Long COVID, sponsored by Washington University School of Medicine.

Completed
Registry status
Phase 2
Development phase
191
Enrollment target
1
Study location

NCT05874037 is a Phase 2 study of Long COVID that has completed, run by Washington University School of Medicine. The registered enrollment target is 191 participants, below the 2,184-participant average among 50 other Long COVID trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05874037, a Phase 2 study of Long COVID, has completed, sponsored by Washington University School of Medicine.

COMPLETED
Registry status
Phase 2
Development phase
191 participants
Enrollment target
1
Study location

Study Summary

This clinical trial aims to test the effects of fluvoxamine as a treatment for Long COVID. Fluvoxamine is an FDA approved SSRI for Obsessive Compulsive Disorder (OCD), that has already had success in preventing hospitalization in patients with COVID-19 (STOP COVID and TOGETHER trials). This trial is testing whether fluoxamine helps to improve symptoms and the negative impacts of long COVID in residents of Missouri and Illinois.

Conditions Studied

Long COVID

Interventions

  • DRUG Fluvoxamine

Study Locations (1)

Missouri

  • Washington University School of Medicine - St Louis

Trial Details

FieldValue
Enrollment Target 191 participants
Start Date 2023-05-15
Est. Completion 2025-03-15
Phase Phase 2

Sponsor

Washington University School of Medicine

1,502 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05874037

The ClinicalTrials.gov registry entry for NCT05874037 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 191 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,184-participant average among 50 other Long COVID trials with a reported enrollment target (91% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Long COVID appearing as the primary indexed condition, and to 1 intervention - of which Fluvoxamine is the first listed.

NCT05874037 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.

Frequently Asked Questions

What is clinical trial NCT05874037 about?

NCT05874037 is a clinical study titled "Fluvoxamine for Long COVID-19". This clinical trial aims to test the effects of fluvoxamine as a treatment for Long COVID. Fluvoxamine is an FDA approved SSRI for Obsessive Compulsive Disorder (OCD), that has already had success in preventing hospitalization in patients with COVID-19 (STOP COVID and TOGETHER trials). This trial is...

What is the current status of trial NCT05874037?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 191 participants. The study started on 2023-05-15. Estimated completion is 2025-03-15.

What conditions does trial NCT05874037 study?

This clinical trial studies the following conditions: Long COVID.

What interventions are being tested in trial NCT05874037?

The interventions under investigation include: Fluvoxamine (DRUG).

Who is sponsoring clinical trial NCT05874037?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05874037 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Long COVID

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Long COVID

All registered trials for this condition

Missouri

All trials with a study site in Missouri

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.